Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Abstract Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …

T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …

Advances in cell-based therapy, particularly CAR-T cell therapy, have transformed the
treatment of hematological malignancies. Although an important step forward for the field …

Current limitations in using chimeric antigen receptor T (CART) cells to treat patients with
hematological cancers include limited expansion and persistence in vivo that contribute to …

Emerging reports show that metabolic pathways can be targeted to enhance T cell-mediated
immunity to tumors. Yet, tumors consume key metabolites in the host to survive, thus robbing …

It is now becoming clear that less differentiated naive and memory T cells are superior to
effector T cells in the transfer of immunity for adoptive cell therapy. This review will outline …

Molecular targeted drugs and chimeric antigen receptor (CAR) T cell therapy represent
specific biological treatments that have significantly improved the efficacy of treating …

Chimeric antigen receptor (CAR) T cell therapy can achieve outstanding response rates in
heavily pretreated patients with hematological malignancies. However, relapses occur and …

CD70 is highly expressed in renal cell carcinoma (RCC), with limited expression in normal
tissue, making it an attractive CAR T target for an immunogenic solid tumor indication. Here …